What does this research mean for the field?

Capillary microsampling, including dried blood spots and volumetric absorptive microsampling, enables accurate venetoclax quantification in leukemia patients when individualized hematocrit-based conversion is applied, and home-based self-microsampling is feasible. Novelty: ClaimNovelty.METHODOLOGICAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

The aim is to validate volumetric microsampling of venetoclax in leukemia patients and assess conversion strategies.

April 25, 2026Open Access

Clinical Validation of Venetoclax Volumetric Microsampling in Patients with Leukemia with Assessment of Whole-Blood-to-Plasma Conversion Strategies and Self-Microsampling Feasibility

Key Points

The aim is to validate volumetric microsampling of venetoclax in leukemia patients and assess conversion strategies.
Evaluated capillary microsampling for venetoclax quantification in AML and CLL patients.
Applied individualized hematocrit-based conversion for accurate results.
Assessed home-based self-microsampling feasibility.
Both DBS and VAMS methods met international validation standards.
Self-microsampling at home proved feasible for patients.
Further studies are warranted to explore decentralized pharmacokinetics monitoring.

Abstract

Capillary microsampling enables accurate venetoclax quantification in patients with AML and CLL when individualized hematocrit-based microsample-to-plasma conversion is applied. Both DBS and VAMS met international validation criteria, and home-based self-microsampling proved feasible. Venetoclax home-based self-microsampling warrants further study as a tool for decentralized PK monitoring.

Bookmark

View Full Paper